Skip to main content
. 2001 Sep 1;15(17):2250–2262. doi: 10.1101/gad.870101

Figure 6.

Figure 6

Missense mutation in human cancer cell lines. (A) Genomic DNA from various cancer cell lines were PCR amplified with the primers RP97 and RP99. PCR product (50 ng) was dotted onto a nitrocellulose filter, which was than hybridized with either the wild-type oligo or mutant oligo. The sole spot that was negative for wild-type oligo but positive for mutant oligo was dotted with Saos2 cell DNA. The other spots were DNAs from 10 hepatoma, 10 breast cancer, 5 lung cancer, 1 osteosarcoma, and 5 melanoma cell lines. (B) PR/SET domain alignment. Part of the RIZ1 PR/SET domain is aligned with those of HRX/MLL, SET1, SUV39H1, and ASH1. The C106 residue of RIZ1 is highlighted in bold. (C) Schematic diagram of the RIZ1 mutations found in human cancers. Full-length RIZ1 peptide (from residue 1 to 1719) and RIZ2 peptide (from residue 201 of RIZ1 to 1719) are shown as horizontal bars. The motifs shown (not to scale) include the PR domain (residue 35–150), Rb-binding motif LXCXE (residue 311–315), zinc-finger motif ZNF (residue 362–510; residue 1130–1480), ER-binding motif LXXLL (residue 962–966), and PR-binding motif (residue 1514–1680). The arrows indicate the three missense mutations described in this study and the frameshift mutation.